arrow
W

Wolfgang M. Brueckl

paracelsus medical university
H指数:23
被引数:1,695

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical management and outcomes of relapsed NSCLC after chemoradiotherapy and durvalumab consolidation: real-world evidence from Germany

德国真实世界证据:化疗联合放疗后复发NSCLC的临床管理与结局:度伐利尤单抗巩固治疗后的情况

2026-07-230
PRE
Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Cohort

曲妥珠单抗德鲁替康(Trastuzumab Deruxtecan)在HER2突变非小细胞肺癌患者中的全身及颅内疗效与安全性:来自TRACER/HERTras真实世界队列的证据

2026-02-240
OAAI
Analysis of baseline interstitial lung abnormality on the risk of checkpoint inhibitor-related pneumonitis and survival in advanced non-small cell lung cancer patients treated with first-line PD-1/ PD-L1 inhibitors

基线间质性肺异常对接受一线PD-1/PD-L1抑制剂治疗的晚期非小细胞肺癌患者中,检查点抑制剂相关肺炎风险及生存的影响分析

2025-03-0118
OA
Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)
2024-04-011
OA
Older patients with EGFR mutation-positive non-small cell lung cancer treated with afatinib in clinical practice: A subset analysis of the non-interventional GIDEON study

在临床实践中使用阿法替尼治疗EGFR突变阳性的老年非小细胞肺癌患者: 非干预性GIDEON研究的子集分析

2023-01-013
PRE
The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions

TP53共突变和免疫微环境对EGFR外显子20插入肺癌预后的影响

2022-07-0118
PRE
A nomogram to predict the recurrence-free survival and analyze the utility of chemotherapy in stage IB non-small cell lung cancer

列线图预测IB期非小细胞肺癌无复发生存期及化疗效用分析

2022-01-018
OAAI
Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV
2021-07-0129
OAAI
Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice

阿法替尼一线治疗EGFR突变非小细胞肺癌的临床实践

2021-05-0611
OAAI